Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.GYRE · Entity 5247 | Director · Chief Executive Officer | June 08, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.05 · Expires 2036-06-08 | Direct | 120,000 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 120,000 · Balance 120,000 F1: This option represents a right to purchase a total of 120,000 shares of the Issuer's common stock, 25% of which will vest on June 8, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 120,000 shares of the Issuer's common stock, 25% of which will vest on June 8, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2026 Filed Jun 10, 2026 20:13 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $6.05 | $0.00 |
DisclosureSEC source: 0001140361-26-024784 · form4.xml · derivative · entry 1 Luo Ying · CIK 0001959160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: This option represents a right to purchase a total of 120,000 shares of the Issuer's common stock, 25% of which will vest on June 8, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| May 06, 2026 Filed May 8, 2026 01:58 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 10,136 | $8.04 | $81,493.44 |
DisclosureSEC source: 0001140361-26-019658 · form4.xml · nonDerivative · entry 2 Luo Ying · CIK 0001959160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,565,226 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.071. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 05, 2026 Filed May 8, 2026 01:58 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 179 | $8.01 | $1,433.79 |
DisclosureSEC source: 0001140361-26-019658 · form4.xml · nonDerivative · entry 1 Luo Ying · CIK 0001959160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,575,362 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025. Read SEC document |
| August 14, 2024 Filed Aug 17, 2024 00:56 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $9.98 | $0.00 |
DisclosureSEC source: 0001140361-24-037707 · form4.xml · derivative · entry 1 Luo Ying · CIK 0001959160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2034-08-14 F1 · derivative.exercise_date: This option represents a right to purchase a total of 26,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through August 14, 2025, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| November 20, 2023 Filed Nov 23, 2023 00:55 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 2,262,755 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-23-054522 · form4.xml · derivative · entry 3 Luo Ying · CIK 0001959160 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 2,262,755 Underlying: Common Stock · 2,262,755 shares Expires 2030-10-31 F3 · derivative.exercise_price: Beijing Continent terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan. F3 · derivative.exercise_date: Beijing Continent terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan. F4 · derivative.exercise_date: These options are vested in full. F3 · derivative.expiration_date: Beijing Continent terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan. Read SEC document |
| November 20, 2023 Filed Nov 23, 2023 00:55 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 3,350,897 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-23-054522 · form4.xml · derivative · entry 2 Luo Ying · CIK 0001959160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,350,897 Underlying: Common Stock · 3,350,897 shares Expires 2030-10-31 F3 · derivative.exercise_price: Beijing Continent terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan. F3 · derivative.exercise_date: Beijing Continent terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan. F4 · derivative.exercise_date: These options are vested in full. F3 · derivative.expiration_date: Beijing Continent terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan. Read SEC document |
| October 31, 2023 Filed Nov 1, 2023 10:15 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 1,866 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001140361-23-050620 · form4.xml · derivative · entry 1 Luo Ying · CIK 0001959160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,866 Underlying: Common Stock · 1,866 shares Expires 2033-10-31 F1 · derivative.exercise_date: These options vest as to one-third on each of the first, second and third anniversaries of October 31, 2023, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| October 30, 2023 Filed Nov 23, 2023 00:55 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | OtherCommon Stock | 2,840,376 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-054522 · form4.xml · nonDerivative · entry 1 Luo Ying · CIK 0001959160 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 2,840,376 F1 · price: Represents the number of shares of common stock of the Issuer received by the spouse of the Reporting Person in exchange for the shares of Aaring Limited, a company incorporated under the laws of Hong Kong with limited liability, held by the spouse of the Reporting Person pursuant to that certain Business Combination Agreement, dated as of December 26, 2022 and as amended on March 29, 2023 and August 30, 2023 (the "Business Combination Agreement"), by and among Catalyst Biosciences, Inc., a Delaware corporation, GNI USA, Inc., a Delaware corporation, GNI Group Ltd., a company incorporated under the laws of Japan with limited liability, F2 · price: [cont'd from FN 1] GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability, Shanghai Genomics, Inc., a company organized under the laws of the People's Republic of China, the Minority Holders (as defined therein) and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares. Pursuant to the terms of the Business Combination Agreement, on October 30, 2023, the Issuer acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.